[Zr-89]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer

E. J. van Helden, S. G. Elias, S. L. Gerritse, S. C. van Es, E. Boon, M. C. Huisman, N. C. T. van Grieken, H. Dekker, G. A. M. S. van Dongen, D. J. Vugts, R. Boellaard, C. M. L. van Herpen, E. G. E. de Vries, W. J. G. Oyen, A. H. Brouwers, H. M. W. Verheul, O. S. Hoekstra, C. W. Menke-van der Houven van Oordt*

*Bijbehorende auteur voor dit werk

OnderzoeksoutputAcademicpeer review

7 Citaten (Scopus)
73 Downloads (Pure)


Purpose One-third of patients with RAS wild-type mCRC do not benefit from anti-EGFR monoclonal antibodies. This might be a result of variable pharmacokinetics and insufficient tumor targeting. We evaluated cetuximab tumor accumulation on [Zr-89]Zr-cetuximab PET/CT as a potential predictive biomarker and determinant for an escalating dosing strategy. Patients and methods PET/CT imaging of [Zr-89]Zr-cetuximab (37 MBq/10 mg) after a therapeutic pre-dose (500 mg/m(2)

Originele taal-2English
Pagina's (van-tot)849-859
Aantal pagina's11
TijdschriftEuropean Journal of Nuclear Medicine and Molecular Imaging
StatusE-pub ahead of print - 9-nov-2019

Citeer dit